ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023
Antivirals With Activity Against Mpox: A Clinically Oriented Review.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 105 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III, Multi-country, Randomized, Placebo-controlled, Double-blinded Trial to Assess the Efficacy and Safety of Tecovirimat Antiviral Treatment for Patients With Monkeypox Virus Disease
European Randomised Clinical Trial on mPOX Infection
Randomized Trial to Evaluate the Efficacy/Effectiveness, Safety, and Immunogenicity of Replicative Live Attenuated Vaccinia Virus Vaccine LC16m8 for Prevention Against Mpox in High-risk Populations During Vaccination Deployment in Colombia
Who cites it
105 citing papers in PubMed, 3 syntheses or guidelines pooled it, 216 citations in OpenAlex.
- A global systematic evidence review with meta-analysis of the epidemiological characteristics of the 2022 Mpox outbreaks.Infection · 2024Pooled it
- Clinical Features, Antiviral Treatment, and Patient Outcomes: A Systematic Review and Comparative Analysis of the Previous and the 2022 Mpox Outbreaks.The Journal of infectious diseases · 2023Pooled it
- Therapeutics for treating mpox in humans.The Cochrane database of systematic reviews · 2023Pooled it
- Discovery of the nucleoside analogue FMAU as a broad-spectrum anti-orthopoxvirus inhibitor in vitro and in vivo using a structure-guided hit expansion strategy.Emerging microbes & infections · 2026Article
- MMF inhibits poxvirus infection by disrupting IMPDH2 interaction with USP5 and inducing its rod-and-ring assemblies.Virologica Sinica · 2026Article
- Exploration of the protein and pharmacological landscape of monkeypox virus treatment: from entry point to end point.Molecular diversity · 2026Review
- Emerging Viral Zoonoses: Epidemiology, Vaccination Strategies, and Implications for Global Public Health.Vaccines · 2026Review
- Recent advances in Mpox across innate immunity, evasion, and clinical outcomes.Communications biology · 2026Review
- Mpox and the one health approach.Dialogues in health · 2026Review
- Treatment of Severe Ocular Mpox with Cidofovir and Tecovirimat.Emerging infectious diseases · 2026Article
- Primary human intestinal organoids model enteric infection of monkeypox virus and enable scalable drug discovery.Science advances · 2026Article
- Monkeypox (Mpox), a Resurging Global Public Health Concern: An Updated Outlook Through 2025.Current issues in molecular biology · 2026Review
- Mpox (Monkeypox) in Pregnancy Updates.Health science reports · 2026Article
- Viral Infections in Kidney Transplant Recipients: Current Practice and Updates.Journal of clinical medicine · 2026Review
- AIEgen-Based Proactive Early Warning System and Precise Treatment Strategy for Monkeypox Prevention and Control.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Targeting endolysosomal acidification inhibits poxvirus entry and replication.Cell communication and signaling : CCS · 2026Article
- 1-Hydroxy-1,8-napthyridinone (DHN) Analogs Potently Inhibit Monkeypox Virus Resolvase (Mpr).Journal of medicinal chemistry · 2026Article
- The Emerging Threat of Monkeypox: An Updated Overview.Viruses · 2026Review
- Disseminated adenovirus infection following CAR T-cell therapy: Early-onset presentation in a patient with relapsed refractory mantle cell lymphoma.Clinical hematology international · 2026Article
- A Multisectoral Study of Mpox Epidemiology, Resistance Surveillance, and Policy Gaps: Toward a One Health Framework.Clinical reviews in allergy & immunology · 2025Review
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mpox virus is an emergent human pathogen. While it is less lethal than smallpox, it can still cause significant morbidity and mortality. In this review, we explore 3 antiviral agents with activity against mpox and other orthopoxviruses: cidofovir, brincidofovir, and tecovirimat. Cidofovir, and its prodrug brincidofovir, are inhibitors of DNA replication with a broad spectrum of activity against multiple families of double-stranded DNA viruses. Tecovirimat has more specific activity against orthopoxviruses and inhibits the formation of the extracellular enveloped virus necessary for cell-to-cell transmission. For each agent, we review basic pharmacology, data from animal models, and reported experience in human patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.